Acknowledgement
This work was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI23C0266).
References
- Chai S, Zhan JL, Zhao LM, Liu XD. Safety of triazole antifungals: a pharmacovigilance study from 2004 to 2021 based on FAERS. Ther Adv Drug Saf 2022;13:20420986221143266.
- Wermers RA, Cooper K, Razonable RR, et al. Fluoride excess and periostitis in transplant patients receiving long-term voriconazole therapy. Clin Infect Dis 2011;52:604-611.
- Klatt ME, Eschenauer GA. Review of pharmacologic considerations in the use of azole antifungals in lung transplant recipients. J Fungi (Basel) 2021;7:76.
- Thompson GR 3rd, Bays D, Cohen SH, Pappagianis D. Fluoride excess in coccidioidomycosis patients receiving long-term antifungal therapy: an assessment of currently available triazoles. Antimicrob Agents Chemother 2012;56:563-564.
- Wang TF, Wang T, Altman R, et al. Periostitis secondary to prolonged voriconazole therapy in lung transplant recipients. Am J Transplant 2009;9:2845-2850.
- Pampaloni MH. Voriconazole-associated periostitis in a heart transplant patient. J Clin Case Rep 2012;2:166.
- Cormican S, Adams N, O'Connell P, McErlean A, de Freitas D. Voriconazole-induced periostitis deformans: serial imaging in a patient with ANCA vasculitis. Skeletal Radiol 2018;47:191-194.
- Reber JD, McKenzie GA, Broski SM. Voriconazole-induced periostitis: beyond post-transplant patients. Skeletal Radiol 2016;45:839-842.
- Li Z, Wu C, Wang C, Deng Z. Spectrum of voriconazole-associated periostitis in clinical characteristics, diagnosis and management. Infection 2022;50:1217-1224.
- Davis DL. Voriconazole-related periostitis presenting on magnetic resonance imaging. Clin Cases Miner Bone Metab 2015;12:78-81.
- Raghavan M, Hayes A. Voriconazole-associated soft tissue ossification: an undescribed cause of glenohumeral joint capsulitis. Skeletal Radiol 2014;43:1301-1305.